 |
 |
 |
| 24小時(shí)熱門(mén)版塊排行榜 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 1 | 1/1 | 返回列表 |
| 查看: 2523 | 回復(fù): 0 | |||
[交流]
西安交通大學(xué)趙四海副教授歡迎有沖勁的年輕學(xué)子報(bào)考（病理學(xué)與病理生理學(xué)碩博生）
|
|
歡迎有志于基礎(chǔ)醫(yī)學(xué)的年輕學(xué)子報(bào)考病理學(xué)與病理生理學(xué)碩博生，推免和統(tǒng)考均可。 如果您初生牛犢不怕虎，如果您為了理想熱血沸騰，如果您經(jīng)歷風(fēng)雨仍保持一顆向前的心，如果您還有童年依稀的科學(xué)夢(mèng)，如果你是一個(gè)敢于吃苦的人，那么我歡迎您到我這里來(lái)。我們實(shí)驗(yàn)室不是校內(nèi)最好的，我的水平也不是國(guó)內(nèi)頂尖的，但是我是最喜歡和學(xué)生做朋友的。在這里，我們有困難共同克服，有成果我愿意和你一起分享，如果需要也可讓你獨(dú)享。我需要的是亦師亦友的學(xué)生，不是唯命是從的隨從。如果你是這樣的人，那么請(qǐng)來(lái)吧！ 聯(lián)系方式： E-mail: sihaizhao@mail.xjtu.edu.cn 電話：029-82655363 82655348 傳真：029-82655362 趙四海，男，35歲，醫(yī)學(xué)博士，副教授，生物學(xué)博士后（出站），病理學(xué)與病理生理學(xué)碩士生導(dǎo)師（2016博士也可以），陜西省科技新星，西安交通大學(xué)優(yōu)秀博士后，陜西省實(shí)驗(yàn)動(dòng)物學(xué)會(huì)副秘書(shū)長(zhǎng)。曾赴日本山梨大學(xué)短期進(jìn)修，在國(guó)內(nèi)外雜志發(fā)表論文72篇，其中SCI收錄48篇(第一/通訊作者27篇)，MI收錄6篇。獲得陜西省高等學(xué)校科技進(jìn)步獎(jiǎng)1項(xiàng)（第一完成人），中國(guó)實(shí)驗(yàn)動(dòng)物學(xué)會(huì)優(yōu)秀青年人才獎(jiǎng)1項(xiàng)，中國(guó)實(shí)驗(yàn)動(dòng)物學(xué)會(huì)科學(xué)技術(shù)二等獎(jiǎng)1項(xiàng)（第二完成人）。 主持國(guó)家自然科學(xué)基金2項(xiàng)（30900526，81370379），中央高校基本科研業(yè)務(wù)費(fèi)專(zhuān)項(xiàng)資金-青年教師跟蹤支持項(xiàng)目（優(yōu)青培育類(lèi)）1項(xiàng)，博士后基金2項(xiàng)（其中特別資助一項(xiàng)），陜西省科技項(xiàng)目2項(xiàng)，西安交通大學(xué)基金3項(xiàng)，參與863項(xiàng)目、國(guó)家自然科學(xué)基金和陜西省重大科技項(xiàng)目多項(xiàng)。 （1）國(guó)家自然科學(xué)基金（81370379）：利用基因敲除家兔研究salusins影響動(dòng)脈粥樣硬化發(fā)生發(fā)展的機(jī)制， 90萬(wàn)元， 2014-01-01至2017-12-31。 （2）國(guó)家自然科學(xué)基金（30900526）：利用轉(zhuǎn)基因兔研究 urotensin II 過(guò)表達(dá)影響動(dòng)脈粥樣硬化進(jìn)程的分子機(jī)制，21萬(wàn)元， 2010-01-01至2012-12-31。 （3）博士后科學(xué)基金（20100471616）：UⅡ/UT在動(dòng)脈粥樣硬化病變中的分布、表達(dá)變化和生物學(xué)功能研究，3萬(wàn)元， 2010-03至2012-12-03。 （4）博士后科學(xué)基金特別資助（201104669）：體內(nèi)輸注尾加壓素Ⅱ?qū)?dòng)脈粥樣硬化形成進(jìn)程影響的分子機(jī)制研究，10萬(wàn)元，2011,09-2013,08。 （5）陜西省科技新星項(xiàng)目（2012KJXX-07）：在體內(nèi)輸salusin-α對(duì)動(dòng)脈粥樣硬化發(fā)生發(fā)展影響的分子機(jī)制研究，10萬(wàn)元，2012,07-2015,06。 教育、工作經(jīng)歷及獲得的榮譽(yù)： 2003年畢業(yè)于青海醫(yī)學(xué)院（現(xiàn)青海大學(xué)醫(yī)學(xué)院）。 2003年起在西安交通大學(xué)連續(xù)攻讀碩士和博士學(xué)位，獲得過(guò)特別優(yōu)秀研究生唐文治獎(jiǎng)學(xué)金和優(yōu)秀畢業(yè)生稱(chēng)號(hào)。 2007年獲得日本動(dòng)脈粥樣硬化學(xué)會(huì)優(yōu)秀外國(guó)青年學(xué)者獎(jiǎng)。 2009年獲西安交通大學(xué)醫(yī)學(xué)博士學(xué)位,留校任教。 2009年進(jìn)入醫(yī)學(xué)院生物學(xué)博士后工作站從事科研工作。 2009和2010年度被醫(yī)學(xué)院授予科研優(yōu)秀獎(jiǎng)。 2012年獲西安交通大學(xué)優(yōu)秀博士后稱(chēng)號(hào)。 2012年被評(píng)為陜西省科技新星。 2013年獲陜西省高等學(xué)�？萍歼M(jìn)步獎(jiǎng)（第一完成人）。 2014年獲評(píng)中國(guó)實(shí)驗(yàn)動(dòng)物學(xué)會(huì)優(yōu)秀青年人才和科學(xué)技術(shù)進(jìn)步二等獎(jiǎng)（第二完成人）。 主要研究方向： （1）動(dòng)脈粥樣硬化形成的分子機(jī)制 （2）抗心血管病藥物的研究 （3）轉(zhuǎn)基因動(dòng)物模型的開(kāi)發(fā) （4）肝病的循證醫(yī)學(xué)分析研究 近年發(fā)表的論文： 1. Yingfeng An, Shoucui Gao, Daxin Cheng, Xiaojing Wang, Liang Bai, Enqi Liu, Yonglie Chu, Sihai Zhao*. Peginterferon and Chinese herbs exert a combinatorial effect in HBeAg-positive chronic hepatitis B. The Journal of Infection in Developing Countries. 2015. Accepted. (* 通訊作者) 2. Wang C, Li Y, Gao S, Cheng D, Zhao S*, Liu E*. Breviscapine Injection Improves the Therapeutic Effect of Western Medicine on Angina Pectoris Patients. PLoS One. 2015;10(6):e0129969. (* 通訊作者) 3. Cheng D, Wang Y, Gao S, Wang X, Sun W, Bai L, Cheng G, Chu Y, Zhao S* and Liu E*. Atorvastatin delays the glucose clearance rate in hypercholesterolemic rabbits. Biomed Pharmacother. 2015;72:24-29. (* 通訊作者) 4. Li Y, Gao S, An Y, Liu E, Zhao S*. High dose atorvastatin therapy yields a better carotid atherosclerosis improvement in Chinese patients. Int J Cardiol. 2015;185:131-132. (* 通訊作者) 5. Huifeng Zhang, Si Guo, Liancai Wang, Yadong Dong, Guanjin Tian, Senmao Mu, Deyu Li, Haibo Yu*, Sihai Zhao*. Single-incision laparoscopic splenectomy should be a safe and effective minimally invasive operation as standard laparoscopic splenectomy. Hepato-Gastroenterology. 2014. Accepted. (* 通訊作者) 6. Haibo Yu, Si Guo, Liancai Wang, Yadong Dong, Guanjin Tian, Senmao Mu, Huifeng Zhang, Deyu Li*, Sihai Zhao*. Laparoscopic splenectomy and esophagogastric devascularization for liver cirrhosis and portal hypertension should be a safe, effective, minimally invasive operation. Hepato-Gastroenterology. 2014. Accepted. (* 通訊作者) 7. Cheng D, Liu E, Chu Y, Gao S, An Y, Bai L, Wu M, Cheng G, Zhao S*. Interferon plus Oxymatrine Achieved Higher Sustained Virological Response than Interferon Alone in Chronic Hepatitis C. Hepato-Gastroenterology. 2014. Accepted. (* 通訊作者) 8. Li Y, Zhao S*，Wang Y, Chen Y, Lin Y, Zhu N, Zheng H, Wu M, Cheng D, Lin Y, Bai L, Fan J, and Liu E*. Urotensin II promotes atherosclerosis in cholesterol-fed rabbits. PLoS One. 2014;9(4):e95089.(* 通訊作者) 9. Cheng D, Liu E, Li Y, Liu R, Bai L, Chen Y, Wang Y, Chu Y, Wu M, Cheng G, Zhao S*. Peginterferon Plus Chinese Herbal Therapy is Associated with a Higher Virological Response than only Peginterferon Therapy in Chronic Hepatitis C. Eur J Clin Microbiol Infect Dis. 2014,33(3):433-438. (* 通訊作者) 10. Zhao S, Liu Enqi, Cheng D, Li Y, Wang Y, Chen Y, Sun W, Yan X, Dang S. Comparison of entecavir and adefovir for the treatment of chronic hepatitis B. Braz J Infect Dis. 2012;16(4):366-72. (* 通訊作者) 11. Zhang G, Wei K, Liu E, Wang Yi, Li Y, Yu Q, Chen Y, Huang B, Lu S, Yan X, Zhao S*. The effects of rosiglitazone on fatty liver of high fat and cholesterol-fed rabbits. J Anim Vet Adv. 2012;(11)14:2564-2569 .(* 通訊作者) 12. Yu Q, Liu E, Zhao S*, Li Y, Wang Y, Wei K, Huang B, Chen Y, Fan J, Yang P. Association of TaqIB Polymorphism of Cholesteryl Ester Transfer Protein and Coronary Artery Disease in Chinese Population. J Zhejiang Univ-Sci B (Biomed & Biotechnol) 2012 13(5):342-347. 13. Zhao S*, Liu E, Wei K, Lu S, Chu Y, Li Y, Wang Y, Huang B, Chen Y, Yang P. Interferon plus Chinese herbs are associated with higher sustained virological response than interferon alone in chronic Hepatitis C: a meta-analysis of randomised trials. Antiviral Res. 2011,89(2):156-164. (* 通訊作者) 14. Zhao S*, Liu E, Wei K, Wang Y, Li Y, Huang B, Chen Y, Yang P. Treatment with peginterferon versus interferon in Chinese patients with chronic hepatitis C. Eur J Clin Microbiol Infect Dis. 2011,30(1):51-57. (* 通訊作者) 15. Yu H, Zhang H*, Li D, Zhang X, Xue H, Zhao S*. Matrine inhibits matrix metalloproteinase-9 expression and invasion of human hepatocellular carcinoma cells. Journal of Asian Natural Products Research. 2011. 3(13): 242–250. (* 通訊作者) 16. Zhao S, Wei K, Yu Q, li Y, cheng F, Wang Y, Yang P, Fan J, liu E. General topic: applications of transgenic rabbits in biomedical research - based on literature search. World Rabbit Science. 2010,18(3):159-167. 17. Zhao S*, Liu E, Chen P, Cheng D, Lu S, Yu Q, Wang Y, Wei K, Yang P. A Comparison of Peginterferon α-2a and Peginterferon α-2b for Patients With Treatment-Naive Chronic Hepatitis C: A Meta-Analysis of Randomized Trials. Clinical therapeutics,2010, 32 (9):1565-1577. (* 通訊作者) 18. Yu H, Liu E, Lu S, Zhao S*. Treatment with peginterferon versus interferon in Chinese patients with hepatitis B. Biomed Pharmacother. 2010,64 (10) 559–564. (* 通訊作者) 19. Yu H, Zhang H*, Zhang X, Li D, Xue H, Pan C, Zhao S*. Resveratrol Inhibits VEGF Expression of Human Hepatocellular Carcinoma Cells through a NF-kappa B-mediated Mechanism. Hepato-Gastroenterology. 2010; 57:1241-1246. (* 通訊作者) 20. Zhao S, Chu Y, Cheng D, Waqar A, Yu Q, Yang P, Xue X, Yang H. Liu E. Treatment with peginterferon plus ribavirin versus interferon plus ribavirin for 48 weeks in Chinese patients with chronic hepatitis C. Int J Clin Pract.2009,63(9):1334-1339. 21. Zhao S, Xun M, Chu Y, Zhu T, Wang Y, Yan L, Xue X, Xu K, Song J, Shao M. Proteome analysis identifies the role of heat stress in production of progeny HCV in Huh7 cells harboring intact HCV. Intervirology. 2008,51(3):196-202. 22. Zhao S, Xun M, Chu Y, Zhu T, Xue X, Xu K, Song J, Shao M. Comparative Proteomics Analysis of Huh7 Cells Harboring Intact HCV. Chemical Journal of Chinese Universities (Chinese Edition). 2008,29(11)2174-2177. 23. Zhao S, Cheng D, Liu E, Yu H, Yang H, Xue X, Chu Y. Peginterferon vs. interferon in the treatment of different HCV genotype infections in HIV patients. European Journal of Clinical Microbiology & Infectious Diseases. 2008, 27 (12):1183–1192. 24. Zhao S, Zhang C, Lin Y, Yang P, Yu Q, Yang P, Chu Y, Fan J, Liu E. The effects of rosiglitazone on aortic atherosclerosis of cholesterol-fed rabbits. Thrombosis Research. 2008,123(2):281-287. 25. Zhao S, Liu E, Yu H, Yang H, Xun M, Xue X, Song J, Xu K, Chu Y. Comparison of peginterferon and interferon in treating Chinese patients with chronic hepatitis C. Hepato-gastroenterology. 2008;55(84):1047-1054. 26. Zhao S, Chu Y, Zhang C, Lin Y, Xu K, Yang P, Fan J, Liu E. Diet-induced central obesity and insulin resistance in rabbits. J Anim Physiol Anim Nutr (Berl). 2008;92(1):105-111. 27. Zhao S, Liu E, Chu Y, Zheng H, Kitajima S, Morimoto M. Numbers of publications related to laboratory animals. Scandinavian Journal of Laboratory Animal Science. 2007; 34(2):81-86. 28. Chen Y, Zhao S, Wang Y, Li Y, Bai L, Liu R, Fan J, Liu E. Homocysteine reduces protein S-nitrosylation in endothelium. Int J Mol Med. 2014 Nov;34(5):1277-85. 29. Wang Y, Bai L, Lin Y, Guan H, Zhu N, Chen Y, Li Y, Gao S, Zhao S, Fan J, Liu E. Demonstration of an add-on effect of probucol and cilostazol on the statin-induced anti-atherogenic effects. Histol Histopathol. 2014;29(12):1593-600. 30. Chen Y, Zhao S, Huang B, Wang Y, Li Y, Waqar AB, Liu R, Bai L, Fan J, Liu E. Probucol and cilostazol exert a combinatorial anti-atherogenic effect in cholesterol-fed rabbits. Thromb Res. 2013;132(5):565-71. 31. Wang Y, Zhao S, Bai L, Fan J, Liu E. Expression systems and species used for transgenic animal bioreactors. BioMed Research International. 2013;2013:580463 32. Zhang R, Yan JD, Valenzuela RK, Lu SM, Du XY, Zhong B, Ren J, Zhao SH, Gao CG, Wang L, Guo TW, Ma J. Further evidence for the association of genetic variants of ZNF804A with schizophrenia and a meta-analysis for genome-wide significance variant rs1344706. Schizophr Res. 2012;141(1):40-7. 33. Yulong Chen, Zhongdong Wang, Guangwei Zhang, Wei Fan, Yuanqing Tao, Xue He, Sihai Zhao, Bingqiao Huang, Jianglin Fan, Kitajima Shuji, Enqi Liu. Genetic characterization of four wild species of Chinese marmots using microsatellite markers. Biologia. 2012. 67(5):1013-1017. 34. Wang Y, Cheng F, Chen Y, Li Y, Zhao S, Yu Q, Fan J, Liu E*. High-Dose Rosiglitazone is Pro-atherogenic in Cholesterol-fed Rabbits. Atherosclerosis. 2012,222(1):292-4. 35. Li Y, Wang Z, Tao Y, Fan W, Li M, Huang B, Zhao S, Fan J, Liu E*. Characteristics of Himalayan Marmots and their response to an atherogenic diet. Exp Anim. 2012;61(4):461-6. 36. Yu Q, Li Y, Wang Y, Yu Y, Zhao S, Chen Y, Waqar AB, Fan J, Liu E*. Expression of TRPV1 in rabbits and consuming hot pepper affects its body weight. Mol Biol Rep. 2012 Jul;39(7):7583-9. 37. Yu Q, Li Y, Waqar AB, Wang Y, Huang B, Chen Y, Zhao S, Yang P, Fan J, Liu E*. Temporal and quantitative analysis of atherosclerotic lesions in diet-induced hypercholesterolemic rabbits. J Biomed Biotechnol. 2012:506159. 38. Yu Q, Li Y, Wang Y, Zhao S, Yang P, Chen Y, Fan J, and Liu E. C-reactive protein levels are associated with the progression of atherosclerotic lesions in rabbits. Histology and Histopathology. Histol Histopathol. 2012,27(4): 529-535. 39. Yu Q, Lin Y, Yang P, Wang Y, Zhao S, Yang P, Fan J, Liu E. C-reactive protein is associated with the progression of acute embolic stroke in rabbit model. J Thromb Thrombolysis. 2012,33(4):301-7. 40. Dang S, Wang W, Wang X, Li Y, Li M, Jia X, Wang Y, Liu E and Zhao S. Telaprevir for Chronic Hepatitis C with Genotype 1: A Meta-Analysis. Hepato-Gastroenterology. 2012.59(114):461-8. 41. Yu H, Li D, Zhang H, Xue H, Pan C, Zhao S. Effects of ANGPTL3 antisense oligodeoxynucleotides transfection on the cell growths and invasion of human hepatocellular carcinoma cells. Hepato-Gastroenterology. 2011.58(110-111):1742-6. 42. Sun W, Lei C, Zhao S, Wang L, Bi C, Wang R, Zhou X, Liu E and Chen M. Histomorphological and Ultrastructural Changes of Retinopathy in Diabetic Rabbit Model. J Anim Vet Adv. 2011,10(2):133-137. 43. Li Y, Wang Y, Yu Q, Wei K, Li M, Zhao S, Kurabayasgi Y, Fan J and Liu E. Compound Danshen dripping pills for stable angina: Meta-analysis of randomized controlled trials. Journal of Medicinal Plants Research. 2011,5(11):2245–2251. 44. Yu H, Li D, Zhang H, Xue H, Pan C, Zhao S, Wang L. Resveratrol Inhibits Invasion and Metastasis of Hepatocellular Carcinoma Cells. J Anim Vet Adv. 2010,9(24):3117-3124. 45. Li Y, Kurabayashi Y, Zhao S, Yu Q, Cheng F, Wang Y, Wei K, Liu E. Meta analysis on acupuncture treatment of aphasia. Zhen Ci Yan Jiu. 2010,35(6):468-473. 46. Chen P, Zhao S, Chu Y, Xu K, Zhua L, Wu Y, Song J, Cao C, Xue X and Niu Y. Anticancer activity of PDSS2, prenyl diphosphate synthase, subunit 2, in gastric cancer tissue and the SGC7901 cell line. Anticancer Drugs. 2009,20(2):141-148. 47. Yu Q, Han W, Wang Y, Wei K, Zhao S, Yang P, Liu E. How effective use Hirsch index to assess a journal? A study of evaluation the Hirsch index of Chinese Medical Journal. J Anim Vet Adv. 2009,8(12):2485-2488. 48. Yu H, Pan C, Zhao S, Wang Z, Zhang H, Wu W. Resveratrol inhibits tumor necrosis factor-a-mediated matrix metalloproteinase-9 expression and invasion of human hepatocellular carcinoma cells. Biomed Pharmacother, 2008,62(6):366- 372. |
回復(fù)此樓» 猜你喜歡
求材料，環(huán)境專(zhuān)業(yè)調(diào)劑
已經(jīng)有3人回復(fù)
-
335求調(diào)劑
已經(jīng)有5人回復(fù)
-
求調(diào)劑
已經(jīng)有7人回復(fù)
-
一志愿吉大化學(xué)322求調(diào)劑
已經(jīng)有4人回復(fù)
-
環(huán)境學(xué)碩288求調(diào)劑
已經(jīng)有8人回復(fù)
-
341求調(diào)劑(一志愿湖南大學(xué)070300)
已經(jīng)有6人回復(fù)
-
一志愿北京化工大學(xué) 070300 學(xué)碩 336分 求調(diào)劑
已經(jīng)有7人回復(fù)
-
299求調(diào)劑
已經(jīng)有5人回復(fù)
-
306求0703調(diào)劑一志愿華中師范
已經(jīng)有8人回復(fù)
-
一志愿河北工業(yè)大學(xué)0817化工278分求調(diào)劑
已經(jīng)有11人回復(fù)
» 本主題相關(guān)商家推薦: (我也要在這里推廣)
相關(guān)版塊跳轉(zhuǎn)
我要訂閱樓主 zhaosige 的主題更新
| 1 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 081700 調(diào)劑 267分 +7 | 迷人的哈哈 2026-03-23 | 7/350 |
|
|---|---|---|---|---|
|
[考研] 335分 | 材料與化工專(zhuān)碩 | GPA 4.07 | 有科研經(jīng)歷 +4 | cccchenso 2026-03-23 | 4/200 |
|
|
|
[考研] 269求調(diào)劑 +4 | 我想讀研11 2026-03-23 | 4/200 |
|
|
|
[考研] 070300化學(xué)求調(diào)劑 +8 | 苑豆豆 2026-03-20 | 8/400 |
|
|
|
[考研] 生物學(xué)一志愿985，分?jǐn)?shù)349求調(diào)劑 +6 | zxts12 2026-03-21 | 9/450 |
|
|
|
[考研]
 材料與化工考研調(diào)劑
+4
|
孅華 2026-03-22 | 4/200 |
|
|
|
[考研] 工科材料085601 279求調(diào)劑 +8 | 困于星晨 2026-03-17 | 10/500 |
|
|
|
[考研] 280分求調(diào)劑 一志愿085802 +4 | PUMPT 2026-03-22 | 7/350 |
|
|
|
[考研] 尋找調(diào)劑 +4 | 倔強(qiáng)芒? 2026-03-21 | 4/200 |
|
|
|
[考研] 275求調(diào)劑 +6 | shansx 2026-03-22 | 8/400 |
|
|
|
[考研] 廣西大學(xué)材料導(dǎo)師推薦 +3 | 夏夏夏小正 2026-03-17 | 5/250 |
|
|
|
[考研] 考研調(diào)劑 +3 | 呼呼？~+123456 2026-03-21 | 3/150 |
|
|
|
[考研] 求調(diào)劑 +3 | 13341 2026-03-20 | 3/150 |
|
|
|
[考研] 297求調(diào)劑 +11 | 戲精丹丹丹 2026-03-17 | 12/600 |
|
|
|
[考研] 302求調(diào)劑 +12 | 呼呼呼。。。。 2026-03-17 | 12/600 |
|
|
|
[考研] 296求調(diào)劑 +4 | www_q 2026-03-20 | 4/200 |
|
|
|
[考研] 一志愿天津大學(xué)化學(xué)工藝專(zhuān)業(yè)（081702）315分求調(diào)劑 +12 | yangfz 2026-03-17 | 12/600 |
|
|
|
[考研] 301求調(diào)劑 +10 | yy要上岸呀 2026-03-17 | 10/500 |
|
|
|
[考研] 303求調(diào)劑 +5 | 睿08 2026-03-17 | 7/350 |
|
|
|
[考研] 332求調(diào)劑 +4 | ydfyh 2026-03-17 | 4/200 |
|